Where does BRPA stock trade?

Big Rock Partners Acquisition Corp. (BRPA) is listed on NASDAQ.

What sector and industry is BRPA in?

Big Rock Partners Acquisition Corp. operates in the Finance sector, Business Services industry.

When did Big Rock Partners Acquisition Corp. go public?

Big Rock Partners Acquisition Corp. (BRPA) completed its IPO in 2017.

What companies are similar to BRPA?

Notable peers in the same industry include FLT (FleetCor Technologies Inc.), NVEI (Nuvei Corporation Subordinate Voting Shares), NLSN (Nielsen N.V.), STMP (Stamps.com Inc.), ENV (Envestnet Inc). Compare BRPA side-by-side with any of them on Quantisnow.

How can I track BRPA on Quantisnow?

Quantisnow aggregates Big Rock Partners Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRPA to receive live email and push alerts on every new disclosure.

BRPA

NASDAQ

Big Rock Partners Acquisition Corp.

SectorFinanceIndustryBusiness ServicesIPO2017

$24.08-6.05 (-20.08%)

News25/Ratings0

Latest news

25 items

1757dPR
NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update
RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to
1831d13D/G
SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)
SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
1831dINSIDER
SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)
4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
1831d13D/G
SEC Form SC 13D filed by Big Rock Partners Acquisition Corp.
SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
1837dSEC
SEC Form 8-K filed by Big Rock Partners Acquisition Corp.
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
1837dSEC
Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
1839d13D/G
SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)
SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)
1839dSEC
SEC Form 8-K filed by Big Rock Partners Acquisition Corp.
8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
1840dINSIDER
SEC Form 4 filed by Big Rock Partners Acquisition Corp.
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
1840dINSIDER
SEC Form 4 filed by Big Rock Partners Acquisition Corp.
4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)
1841dPR
NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)
RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr
1841dSEC
SEC Form 25-NSE filed by Big Rock Partners Acquisition Corp.
25-NSE - Big Rock Partners Acquisition Corp. (0001719406) (Subject)
1841dSEC
SEC Form 25-NSE filed by Big Rock Partners Acquisition Corp.
25-NSE - Big Rock Partners Acquisition Corp. (0001719406) (Subject)
1842dSEC
SEC Form EFFECT filed by Big Rock Partners Acquisition Corp.
EFFECT - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1844dPR
Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx
Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state
1844dSEC
SEC Form 424B3 filed by Big Rock Partners Acquisition Corp.
424B3 - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1845dSEC
SEC Form S-4/A filed by Big Rock Partners Acquisition Corp. (Amendment)
S-4/A - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1846dSEC
SEC Form S-4/A filed by Big Rock Partners Acquisition Corp. (Amendment)
S-4/A - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1851dSEC
SEC Form NT 10-Q filed by Big Rock Partners Acquisition Corp.
NT 10-Q - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1852dSEC
SEC Form 425 filed by Big Rock Partners Acquisition Corp.
425 - Big Rock Partners Acquisition Corp. (0001719406) (Subject)
1854dSEC
Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8-K - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1867dPR
NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia
RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure. The EAP will be conducted in collaboration with Denk Pharma Georgia, Georgia's primary pharmaceutical distributor, and under the auspices of the Potomac Institute of Policy Studies and the Richard G. Lugar Center for Public Health Research, a research facility funded by the U.S. Defense Threat Reduction Agency and named in
1870dPR
Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team
RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The study will be carried out across the United States as part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to prioritize and accelerate development of the most promising COVID-19 treatments. NeuroRx is designated by NIH as an industry partne
1874dSEC
Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - Big Rock Partners Acquisition Corp. (0001719406) (Filer)
1876dSEC
SEC Form 425 filed by Big Rock Partners Acquisition Corp.
425 - Big Rock Partners Acquisition Corp. (0001719406) (Subject)

BRPA FAQ

5 questions

Where does BRPA stock trade?
Big Rock Partners Acquisition Corp. (BRPA) is listed on NASDAQ.
What sector and industry is BRPA in?
Big Rock Partners Acquisition Corp. operates in the Finance sector, Business Services industry.
When did Big Rock Partners Acquisition Corp. go public?
Big Rock Partners Acquisition Corp. (BRPA) completed its IPO in 2017.
What companies are similar to BRPA?
Notable peers in the same industry include FLT (FleetCor Technologies Inc.), NVEI (Nuvei Corporation Subordinate Voting Shares), NLSN (Nielsen N.V.), STMP (Stamps.com Inc.), ENV (Envestnet Inc). Compare BRPA side-by-side with any of them on Quantisnow.
How can I track BRPA on Quantisnow?
Quantisnow aggregates Big Rock Partners Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRPA to receive live email and push alerts on every new disclosure.